New drug QRX-3 aims to speed kidney recovery in hospital patients
NCT ID NCT07161843
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tests an investigational drug called QRX-3 in 500 hospitalized adults and children with acute kidney failure caused by tubular necrosis. The goal is to see if adding QRX-3 to standard care improves kidney function faster than placebo. Participants must have a confirmed diagnosis and no high bleeding risk or prior dialysis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RENAL FAILURE (ARF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neukidney Inc
Rosharon, Texas, 77583, United States
Conditions
Explore the condition pages connected to this study.